Literature DB >> 1336495

Retrovirus-mediated gene transfer targeted to malignant glioma cells in murine brain.

M Yamada1, K Shimizu, Y Miyao, T Hayakawa, K Ikenaka, K Nakahira, K Nakajima, T Kagawa, K Mikoshiba.   

Abstract

A murine model for meningeal metastasis of malignant glioma was developed to study selective gene transfer into tumor cells and to establish a reliable means of determining the rate of tumor cell infection. A murine ecotropic retroviral vector was created in which the Escherichia coli beta-galactosidase gene served as a marker for gene expression from the integrated retrovirus. This retrovirus exhibited a high rate of infectivity in RSV-M mouse glioma cells in vitro. The recombinant retrovirus was injected directly into the cisterna magna of the mice. Staining of beta-galactosidase showed that the rate of gene integration was high in the disseminated glioma cells. These results suggest the possibility of retrovirus-mediated gene therapy for meningeal dissemination of malignant glioma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336495      PMCID: PMC5918741          DOI: 10.1111/j.1349-7006.1992.tb02752.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


5‐bromo‐4‐chloro‐3‐indolyl‐β‐galactoside neomycin phosphotransferase β‐galactosidase simian virus 40
  12 in total

1.  Selective elimination of recombinant genes in vivo with a suicide retroviral vector.

Authors:  G Plautz; E G Nabel; G J Nabel
Journal:  New Biol       Date:  1991-07

2.  Murine model of leptomeningeal dissemination using human medulloblastoma cells.

Authors:  M Yamada; K Shimizu; K Tamura; S Moriuchi; E Mabuchi; K C Park; Y Miyao; T Hayakawa
Journal:  Neurol Med Chir (Tokyo)       Date:  1991-12       Impact factor: 1.742

3.  Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer.

Authors:  J Price; D Turner; C Cepko
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

4.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.

Authors:  R Mann; R C Mulligan; D Baltimore
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

5.  Development of experimental meningeal gliomatosis models in rats.

Authors:  T Yoshida; K Shimizu; Y Ushio; T Hayakawa; N Arita; H Mogami
Journal:  J Neurosurg       Date:  1986-10       Impact factor: 5.115

6.  Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy.

Authors:  B E Huber; C A Richards; T A Krenitsky
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

7.  Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene.

Authors:  Z D Ezzeddine; R L Martuza; D Platika; M P Short; A Malick; B Choi; X O Breakefield
Journal:  New Biol       Date:  1991-06

8.  Detection of brain-specific gene expression in brain cells in primary culture: a novel promoter assay based on the use of a retrovirus vector.

Authors:  K Ikenaka; K Nakahira; K Nakajima; I Fujimoto; T Kagawa; M Ogawa; K Mikoshiba
Journal:  New Biol       Date:  1992-01

9.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.

Authors:  K W Culver; Z Ram; S Wallbridge; H Ishii; E H Oldfield; R M Blaese
Journal:  Science       Date:  1992-06-12       Impact factor: 47.728

10.  A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector.

Authors:  S Kuriyama; M Yoshikawa; S Ishizaka; T Tsujii; K Ikenaka; T Kagawa; N Morita; K Mikoshiba
Journal:  Cell Struct Funct       Date:  1991-12       Impact factor: 2.212

View more
  3 in total

Review 1.  Anti-tumor gene therapy.

Authors:  C Cirielli; M C Capogrossi; A Passaniti
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

Review 2.  Gene therapy in surgical oncology.

Authors:  S P Gagandeep; G J Poston; A R Kinsella
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

3.  Infectious retrovirus is inactivated by serum but not by cerebrospinal fluid or fluid from tumor bed in patients with malignant glioma.

Authors:  K Shimizu; Y Miyao; M Tamura; H Kishima; M Ohkawa; E Mabuchi; M Yamada; T Hayakawa; K Ikenaka
Journal:  Jpn J Cancer Res       Date:  1995-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.